SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, in
| Condition(s) | All Tumor Types |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | SPECTA is a quality assured platform for collecting clinicopathologically annotated biological material, imaging data, operative images, environmental assessment, questionnaires as well as patient-reported outcomes from cancer patients to support biospecimen-based translational research and clinical cancer research, including biomarker discovery to improve the understanding of tumor biology and cancer patients care. |
| Who can participate | * Patients with pathologically confirmed selected tumor types (at site or centrally); * Mandatory availability of adequate human biological material (HBM); * Centrally performed confirmation of HBM adequacy in terms of quality and quantity for SPECTA downstream project requirements; * Age ≥ 12 years; * Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; * Written informed consent according to applicable legal and ethical requirements; |
| Ages | 12 Years |
| Sex | All |
| Lead sponsor | European Organisation for Research and Treatment of Cancer - EORTC |
| Locations | Vienna, Austria; Aalst, Belgium; Antwerp, Belgium; Brussels, Belgium; Brussels, Belgium; Brussels, Belgium (+128 more sites) |
| Start date | 2017-05-03 |
| NCT ID | NCT02834884 |
| Official listing | https://clinicaltrials.gov/study/NCT02834884 |